Gerstein HC, Pais P, Pogue J, et al
Based on evidence from completed cardiovascular and kidney outcome trials, organizations like the American Diabetes Association (ADA), the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE), the American College of Cardiology (ACC), and Kidney Disease: Improving Global Outcomes (KDIGO) note the glycemic, weight, and organ protective benefits of GLP-1 RAs
The strongest evidence layer in this stack
Long-term HFD consumption increased hepatic IKK- glutathionylation and NF-B suppression The mechanistic investigations in our cell culture studies provided evidence suggesting that intracellular GSSG accumulation sensitizes hepatocytes to TNF cytotoxicity via the induction of IKK- glutathionylation, leading to reduced IKK- phosphorylation and subsequent NF-B suppression
Note that TRIUMPH-3 is the cardiovascular-disease population, not the diabetes trial
RA disease activity trended higher among users, with 28% showing moderate or severe symptoms, compared 14% of the non-user group